---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-050671"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2025-11-07T23:59:59+00:00"
generated_at: "2026-05-16T23:05:14.218481+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences cuts 70% of workforce (~31 employees) as part of strategic review

## Summary
- Workforce reduction of ~31 employees (approx. 70% of total staff) announced on Nov 6, 2025.
- Estimated cash expenditures of ~$6.0M for severance and benefits, majority recognized in Q4 2025.
- Restructuring linked to previously announced evaluation of strategic alternatives for the company.
- Company may incur additional costs; will amend filing if material changes arise.

## SEC filing metadata
- accession: 0001628280-25-050671
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2025-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000162828025050671/0001628280-25-050671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000162828025050671/kzr-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-050671
- JSON: https://secwatch.observer/filing/0001628280-25-050671.json
- Plain text: https://secwatch.observer/filing/0001628280-25-050671.txt

## Source-grounded claims
- claim_id: ac1acdbf20031fce7f84843b55787423bd6fe7e3
  claim: Kezar Life Sciences, Inc. announced a restructuring with charges of approximately $6.0 million affecting the Company (approximately 31 employees, or approximately 70%).
  evidence_excerpt: restructuring plan in connection with its previously announced evaluation of strategic alternatives. The Company estimates that it will incur cash expenditures of approximately $6.0 million, consisting primarily of one-time severance payments, benefits and other related costs. The Company expects to recognize the majority of such costs in the fourth quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645666/000162828025050671/0001628280-25-050671-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.